FR06C0024I1 - - Google Patents

Info

Publication number: FR06C0024I1
Authority: FR; France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-01-25

Filing date

2006-07-27

Publication date

2006-10-13

2006-07-27 Application filed filed Critical

2006-10-13 Publication of FR06C0024I1 publication Critical patent/FR06C0024I1/fr

2009-01-02 Application granted granted Critical

2009-01-02 Publication of FR06C0024I2 publication Critical patent/FR06C0024I2/en

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hematology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

FR06C0024C 1994-01-25 2006-07-27 HUMANIZED ANTIBODIES DIRECTED AGAINST THE LEUKOCYTE ADHESION MOLECULE VLA-4 Active FR06C0024I2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US18626994A	1994-01-25	1994-01-25
PCT/US1995/001219 WO1995019790A1 (en)	1994-01-25	1995-01-25	Humanized antibodies against leukocyte adhesion molecule vla-4

Publications (2)

Publication Number	Publication Date
FR06C0024I1 true FR06C0024I1 (en)	2006-10-13
FR06C0024I2 FR06C0024I2 (en)	2009-01-02

Family

ID=22684288

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR06C0024C Active FR06C0024I2 (en)	1994-01-25	2006-07-27	HUMANIZED ANTIBODIES DIRECTED AGAINST THE LEUKOCYTE ADHESION MOLECULE VLA-4

Country Status (21)

Country	Link
EP (2)	EP0804237B8 (en)
JP (5)	JP4115517B2 (en)
KR (1)	KR100367948B1 (en)
CN (1)	CN1211123C (en)
AT (1)	ATE333895T1 (en)
AU (1)	AU703152B2 (en)
CA (1)	CA2182013C (en)
DE (2)	DE122006000043I1 (en)
DK (2)	DK1759709T3 (en)
ES (2)	ES2424292T3 (en)
FI (1)	FI117509B (en)
FR (1)	FR06C0024I2 (en)
HU (1)	HU220799B1 (en)
LU (1)	LU91271I2 (en)
MX (1)	MX9602971A (en)
NL (1)	NL300238I2 (en)
NO (3)	NO319867B1 (en)
NZ (1)	NZ279730A (en)
PL (1)	PL181827B1 (en)
PT (1)	PT804237E (en)
WO (1)	WO1995019790A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6307025B1 (en)	1989-04-28	2001-10-23	Biogen, Inc.	VCAM fusion proteins and DNA coding therefor
US5871734A (en) *	1992-01-13	1999-02-16	Biogen, Inc.	Treatment for asthma with VLA-4 blocking agents
US5932214A (en)	1994-08-11	1999-08-03	Biogen, Inc.	Treatment for inflammatory bowel disease with VLA-4 blockers
NZ261259A (en)	1993-01-12	1996-12-20	Biogen Inc	Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
JP3593343B2 (en) *	1993-02-09	2004-11-24	バイオジェンインコーポレイテッド	Treatment of insulin-dependent diabetes
US7435802B2 (en)	1994-01-25	2008-10-14	Elan Pharaceuticals, Inc.	Humanized anti-VLA4 immunoglobulins
US5840299A (en) *	1994-01-25	1998-11-24	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en)	1995-09-01	2010-09-28	Millennium Pharmaceuticals, Inc.	Mucosal vascular addressing and uses thereof
US6551593B1 (en)	1995-02-10	2003-04-22	Millennium Pharmaceuticals, Inc.	Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7750137B2 (en)	1995-09-01	2010-07-06	Millennium Pharmaceuticals, Inc.	Mucosal vascular addressins
US7147851B1 (en) *	1996-08-15	2006-12-12	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with α4β7 integrin
AU7348798A (en) *	1997-05-09	1998-12-08	John P. Robarts Research Institute, The	Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (en)	1997-09-18	1999-03-25	Hoechst Marion Roussel De Gmbh	Novel imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them
DE19741873A1 (en) *	1997-09-23	1999-03-25	Hoechst Marion Roussel De Gmbh	New 5-ring heterocycles, their preparation, their use and pharmaceutical preparations containing them
DE19751251A1 (en)	1997-11-19	1999-05-20	Hoechst Marion Roussel De Gmbh	Substituted imidazolidine derivatives, their manufacture, their use and pharmaceutical preparations containing them
DE19821483A1 (en)	1998-05-14	1999-11-18	Hoechst Marion Roussel De Gmbh	New imidazolidine derivatives useful as leukocyte adhesion and migration inhibitors and/or VLA-4 receptor antagonists for treating E.G. inflammatory and allergic disorders
SK287601B6 (en) *	1998-09-14	2011-03-04	Board Of Regents, The University Of Texas System	Use of antibody or antigen-binding fragment thereof for the preparation of pharmaceutical composition for treating multiple myeloma and inhibiting bone resorption.
US7618630B2 (en)	1998-09-14	2009-11-17	Board Of Regents, The University Of Texas System	Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
CN100360183C (en)	1999-04-22	2008-01-09	比奥根艾迪克Ma公司	Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
DE19922462A1 (en)	1999-05-17	2000-11-23	Aventis Pharma Gmbh	New phenylureidobenzyl-substituted spiro-imidazolidinedione derivatives, are inhibitors of leukocyte adhesion or migration or VLA-4 receptors, useful e.g. for treating inflammatory or allergic disease
DK2314315T3 (en)	1999-06-01	2015-02-02	Biogen Idec Inc	Blocking monoclonal antibody to the human alpha1-I domain of VLA-1 and their use for the treatment of inflammatory diseases
US6949245B1 (en)	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP2140881B1 (en) *	1999-12-16	2013-04-17	Biogen Idec MA Inc.	Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
DE10111877A1 (en)	2001-03-10	2002-09-12	Aventis Pharma Gmbh	Novel imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them
NZ529494A (en)	2001-04-13	2005-08-26	Biogen Idec Inc	Antibodies to VLA-1
DE10137595A1 (en)	2001-08-01	2003-02-13	Aventis Pharma Gmbh	New 3-alkylaminoalkyl-imdazolidin-4-one derivatives, are VLA-4 receptor and leukocyte adhesion and/or migration inhibitors, useful e.g. for treating inflammatory, allergic, autoimmune or cardiovascular disease
SI1485127T1 (en)	2002-02-25	2011-09-30	Elan Pharm Inc	Administration of agents for the treatment of inflammation
JP2005535572A (en) *	2002-04-12	2005-11-24	メディミューン，インコーポレーテッド	Recombinant anti-interleukin-9 antibody
GB0210121D0 (en)	2002-05-02	2002-06-12	Celltech R&D Ltd	Biological products
AR040778A1 (en) *	2002-08-06	2005-04-20	Glaxo Group Ltd	ALTERED ANTIBODIES OR FUNCTIONAL FRAGMENTS THAT BIND MAG (GLICOPROTEIN ASSOCIATED WITH HONEY).
PT1572748E (en) *	2002-12-17	2010-09-28	Merck Patent Gmbh	Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
CU23403A1 (en) *	2003-04-23	2009-08-04	Centro Inmunologia Molecular	RECOMBINANT ANTIBODIES AND FRAGMENTS RECOGNIZING GANGLIOSIDE N-GLICOLIL GM3 AND ITS USE FOR DIAGNOSIS AND TUMOR TREATMENT
KR101194176B1 (en)	2003-12-22	2012-10-24	아지노모토 가부시키가이샤	Novel phenylalanine derivative
EP1827491A4 (en) *	2004-11-19	2010-07-14	Biogen Idec Inc	Treatment for multiple sclerosis
CA2629147A1 (en) *	2005-11-17	2007-05-31	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin
EP2839843B1 (en)	2006-05-25	2018-06-20	Biogen MA Inc.	VLA-1 antagonist for use in treating stroke
US20100150915A1 (en)	2007-02-20	2010-06-17	Stewart Edward J	Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
LT2170390T (en) *	2007-06-14	2019-01-10	Biogen Ma Inc.	Natalizumab antibody formulations
JP5603082B2 (en)	2007-12-13	2014-10-08	株式会社トクヤマ	Photochromic curable composition
KR20110008086A (en)	2008-04-11	2011-01-25	메리맥 파마슈티컬즈, 인크.	Human Serum Albumin Linker and Conjugates thereof
CN102388068B (en)	2009-03-20	2015-05-20	安姆根有限公司	Alpha-4-beta-7 heterodimer specific antagonist antibody
WO2011020874A1 (en)	2009-08-20	2011-02-24	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
ES2805873T3 (en)	2010-04-16	2021-02-15	Biogen Ma Inc	Anti-VLA-4 antibodies
UA116189C2 (en)	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	COMPOSITION OF ANTI-α4β7 ANTIBODY
AU2012250872B2 (en)	2011-05-02	2017-07-13	Millennium Pharmaceuticals, Inc.	Formulation for anti-alpha4beta7 antibody
WO2013123114A2 (en)	2012-02-16	2013-08-22	Santarus, Inc.	Antibody formulations
WO2018002036A1 (en)	2016-06-28	2018-01-04	Zaklady Farmaceutyczne Polpharma Sa	Recombinant production of monoclonal antibodies
US20190374639A1 (en)	2016-11-21	2019-12-12	Polpharma Biologics S.A.	Aqueous pharmaceutical formulations
EP4659808A2 (en) *	2017-02-17	2025-12-10	Sanofi	Multispecific binding molecules having specificity to dystroglycan and laminin-2
EP3635093A1 (en)	2017-06-08	2020-04-15	Polpharma Biologics S.A.	Improved methods of cell culture
CN112867394B9 (en)	2018-06-04	2024-12-06	马萨诸塞州渤健公司	Anti-VLA-4 antibodies with reduced effector function
US20240301512A1 (en)	2021-01-29	2024-09-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) *	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL95501A (en) *	1989-09-01	1997-04-15	Hutchinson Fred Cancer Res	Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
EP0625912B1 (en) *	1992-02-12	1997-04-16	Biogen, Inc.	Treatment for inflammatory bowel disease
NZ261259A (en) *	1993-01-12	1996-12-20	Biogen Inc	Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
AUPP647298A0 (en)	1998-10-13	1998-11-05	Keystone Retaining Wall Systems, Inc.	Retaining wall block

1995
- 1995-01-25 WO PCT/US1995/001219 patent/WO1995019790A1/en not_active Ceased
- 1995-01-25 CA CA002182013A patent/CA2182013C/en not_active Expired - Lifetime
- 1995-01-25 DK DK06013916.9T patent/DK1759709T3/en active
- 1995-01-25 JP JP51977095A patent/JP4115517B2/en not_active Expired - Lifetime
- 1995-01-25 DE DE1995635133 patent/DE122006000043I1/en active Pending
- 1995-01-25 PT PT95908741T patent/PT804237E/en unknown
- 1995-01-25 CN CNB951913549A patent/CN1211123C/en not_active Expired - Lifetime
- 1995-01-25 ES ES06013916T patent/ES2424292T3/en not_active Expired - Lifetime
- 1995-01-25 AU AU16960/95A patent/AU703152B2/en not_active Expired
- 1995-01-25 KR KR1019960703987A patent/KR100367948B1/en not_active Expired - Lifetime
- 1995-01-25 EP EP95908741A patent/EP0804237B8/en not_active Expired - Lifetime
- 1995-01-25 PL PL95315634A patent/PL181827B1/en unknown
- 1995-01-25 ES ES95908741T patent/ES2270425T3/en not_active Expired - Lifetime
- 1995-01-25 NZ NZ279730A patent/NZ279730A/en not_active IP Right Cessation
- 1995-01-25 DK DK95908741T patent/DK0804237T3/en active
- 1995-01-25 EP EP06013916A patent/EP1759709B1/en not_active Expired - Lifetime
- 1995-01-25 AT AT95908741T patent/ATE333895T1/en active
- 1995-01-25 DE DE69535133T patent/DE69535133T2/en not_active Expired - Lifetime
- 1995-01-25 HU HU9602019A patent/HU220799B1/en active Protection Beyond IP Right Term
1996
- 1996-07-24 NO NO19963097A patent/NO319867B1/en not_active IP Right Cessation
- 1996-07-24 MX MX9602971A patent/MX9602971A/en unknown
- 1996-07-24 FI FI962958A patent/FI117509B/en active Protection Beyond IP Right Term
2005
- 2005-08-05 JP JP2005228930A patent/JP2006045237A/en not_active Withdrawn
2006
- 2006-07-27 FR FR06C0024C patent/FR06C0024I2/en active Active
- 2006-08-02 NL NL300238C patent/NL300238I2/en unknown
- 2006-08-02 LU LU91271C patent/LU91271I2/en unknown
- 2006-08-07 NO NO2006008C patent/NO2006008I2/en unknown
2009
- 2009-05-18 JP JP2009120421A patent/JP2009235078A/en not_active Withdrawn
2013
- 2013-02-18 JP JP2013028635A patent/JP5487382B2/en not_active Expired - Lifetime
- 2013-03-18 JP JP2013054628A patent/JP2013165718A/en not_active Withdrawn
2017
- 2017-08-01 NO NO2017040C patent/NO2017040I2/en unknown

Also Published As

Publication number	Publication date
EP0804237A1 (en)	1997-11-05
HUT75129A (en)	1997-04-28
FR06C0024I2 (en)	2009-01-02
EP0804237A4 (en)	2003-04-16
PT804237E (en)	2006-10-31
AU1696095A (en)	1995-08-08
PL181827B1 (en)	2001-09-28
FI962958L (en)	1996-09-24
NZ279730A (en)	1998-04-27
JPH09508272A (en)	1997-08-26
ES2424292T3 (en)	2013-09-30
DE122006000043I1 (en)	2007-02-15
HU220799B1 (en)	2002-05-28
KR970700513A (en)	1997-02-12
MX9602971A (en)	1998-01-31
CA2182013C (en)	2007-07-17
JP5487382B2 (en)	2014-05-07
AU703152B2 (en)	1999-03-18
NO319867B1 (en)	2005-09-26
NO963097D0 (en)	1996-07-24
NL300238I1 (en)	2006-10-02
ES2270425T3 (en)	2007-04-01
DE69535133D1 (en)	2006-09-07
ATE333895T1 (en)	2006-08-15
NO2017040I1 (en)	2017-08-01
EP1759709A1 (en)	2007-03-07
NO2017040I2 (en)	2018-08-28
DE69535133T2 (en)	2008-08-21
WO1995019790A1 (en)	1995-07-27
DK1759709T3 (en)	2013-06-10
DK0804237T3 (en)	2006-10-16
CN1140413A (en)	1997-01-15
JP2009235078A (en)	2009-10-15
NO2006008I2 (en)	2009-06-15
NO2006008I1 (en)	2006-08-07
PL315634A1 (en)	1996-11-25
NO963097L (en)	1996-09-24
JP2006045237A (en)	2006-02-16
EP0804237B8 (en)	2006-11-08
NL300238I2 (en)	2007-05-01
EP1759709B1 (en)	2013-02-27
FI117509B (en)	2006-11-15
KR100367948B1 (en)	2003-07-12
JP2013173738A (en)	2013-09-05
HU9602019D0 (en)	1996-09-30
JP2013165718A (en)	2013-08-29
JP4115517B2 (en)	2008-07-09
LU91271I2 (en)	2006-10-02
CA2182013A1 (en)	1995-07-27
EP0804237B1 (en)	2006-07-26
CN1211123C (en)	2005-07-20
FI962958A0 (en)	1996-07-24

Publication	Publication Date	Title
FR15C0089I1 (en)	2016-12-02
FR06C0024I1 (en)	2006-10-13
EP0666525A3 (en)	1995-09-20
BRPI9507160A (en)	1997-09-09
FR2727971B1 (en)	1997-02-14
TW272254B (en)	1996-03-11
TW284931B (en)	1996-09-01
BR9509661A (en)	1997-12-23
EP0667627A3 (en)	1995-09-27
BY1704C1 (en)	1997-09-30
IN190348B (en)	2003-07-19
IN188508B (en)	2002-10-05
BRPI9401073A2 (en)	1995-12-05
IN178720B (en)	1997-06-14
IN182474B (en)	1999-04-17
IN187752B (en)	2002-06-15
EP0662420A3 (en)	1995-08-23
BR7402097U (en)	1996-11-19
BR7402039U (en)	1996-11-12
NO942394D0 (en)	1994-06-23
ECSMU940035U (en)	1994-11-16
CN3023289S (en)	1994-02-02
EP0665582A3 (en)	1995-08-16
EP0668066A3 (en)	1995-09-27
EP0664551A3 (en)	1995-08-30